Peripheral Microvascular Serotoninergic Signaling is Dysregulated in Young Adults with Major Depressive Disorder.
Dysfunction of the brain serotonergic system is implicated in the pathogenesis of Major Depressive Disorder (MDD). Serotonin is also a vasoactive signaling molecule, the effects of which are modulated by both nitric oxide (NO) and the serotonin transporter [the primary target of selective serotonin reuptake inhibitors (SSRI)]. Despite its role in the neurobiology of depression, serotoninergic signaling mechanisms in the microvasculature of adults with MDD are unknown. We hypothesized that 1) cutaneous microvascular responsiveness to serotonin would be attenuated in MDD and mediated by reductions in both 2) NO-dependent and 3) serotonin reuptake-dependent mechanisms. In twelve adults with MDD (non-medicated) and twelve non-depressed adults, red cell flux (laser-Doppler flowmetry) was measured during graded intradermal microdialysis perfusion of 1) serotonin (10-10 to 10-1 mol/L) alone and in combination with a non-selective NO synthase inhibitor (L-NAME; 15mmol/L) and the SSRI paroxetine (10μmol/L) and 2) paroxetine (n=6; 10-9 to 10-2 M) alone and in combination with L-NAME. Serotonin-induced vasodilation was preserved in MDD. The NO-dependent component of serotonin-induced vasodilation was not different between groups. Paroxetine augmented vasodilatory responsiveness to serotonin via NO-dependent mechanisms in both groups; however, the magnitude was blunted in MDD. The NO contribution to direct paroxetine-induced vasodilation was also reduced in adults with MDD. Collectively, these preliminary data suggest that cutaneous microvascular serotoninergic signaling is dysregulated in adults with MDD and mediated by NO-dependent and serotonin reuptake-dependent mechanisms, providing intitial mechanistic insight to the purported vasculoprotective effect of chronic SSRI treatment.